True North News

📔 Topics ℹ️ About

Topic: FDA and Public Health Regulation

FDA and Public Health Regulation

2 Stories

2 Related Topics

📊 Analysis Summary

Alternative Data 10 Facts

This week’s mainstream coverage focused on two FDA actions: HHS Secretary Robert F. Kennedy Jr.-backed withdrawal of a long‑planned rule to ban under‑18 indoor tanning and require adult risk acknowledgments, a move public‑health experts warn could increase preventable skin cancers; and approval of a higher‑dose Wegovy HD (7.2 mg semaglutide) for chronic weight management, which showed greater average weight loss in trials but raised questions about higher rates of injection‑site skin sensitivity and known GLP‑1 side effects. Reports noted the FDA framed the tanning decision around “scientific and technical concerns” and described the Wegovy HD approval as part of the agency’s National Priority Voucher pilot to speed products for national health priorities.

What mainstream stories largely omitted were disaggregated and contextual data that change how readers judge both decisions: low current adolescent indoor‑tanning prevalence (about 3% in 2020), existing state minor‑ban laws (22 states + DC), racial differences in melanoma incidence and survival, and long‑term tanning trends; and for Wegovy, clear population and equity context such as racial disparities in GLP‑1 prescribing (Black people are underprescribed relative to need), obesity and diabetes prevalence by race, and questions about who will get access or use higher doses for medical versus cosmetic reasons. Alternative sources and research also highlighted survival and diagnosis disparities for melanoma and heritability estimates for diabetes that mainstream accounts didn’t include. No organized contrarian viewpoints beyond industry pushback were identified in the materials provided, but readers would benefit from more detail on equity, long‑term safety, and regulatory‑policy tradeoffs that were not fully covered.

Summary generated: March 24, 2026 at 11:05 PM

FDA Approves 7.2 mg Wegovy HD Shot for Greater Weight Loss

21h Developing 1

The U.S. Food and Drug Administration has approved Wegovy HD, a new 7.2 mg injection of semaglutide from Novo Nordisk that triples the previous maximum 2.4 mg dose and is indicated for chronic weight management in adults with obesity or overweight plus at least one weight‑related condition. The decision, announced Thursday, is the fourth approval under the FDA’s National Priority Voucher pilot, which Commissioner Dr. Martin Makary says is meant to fast‑track products that address critical national health priorities such as obesity. Clinical data from the STEP UP trial showed patients on the higher dose lost an average of 20.7% of their body weight versus about 16% on the standard dose, with roughly one‑third losing 25% or more, while blood‑sugar reductions in people with type 2 diabetes were similar to the lower dose. The agency says the safety profile mirrors known GLP‑1 side effects like nausea, vomiting and abdominal pain but notes more frequent skin sensitivity and burning at higher doses, which it is investigating, and it warns the drug should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Obesity and diabetes specialists say the new dose creates an evidence‑based escalation path for patients who plateau on 2.4 mg, though they caution it should be reserved for serious obesity management rather than cosmetic weight loss.

Obesity Drugs and GLP‑1 Therapies FDA and Public Health Regulation

FDA Withdraws Proposed Under‑18 Indoor Tanning Ban Backed by RFK Jr.

The Food and Drug Administration has formally withdrawn a long‑planned rule that would have banned people under 18 from using tanning beds and required adult users to periodically sign risk‑acknowledgment forms, reversing a cancer‑prevention push that began in 2015. In a memo signed by Health and Human Services Secretary Robert F. Kennedy Jr., the agency cited unspecified 'scientific and technical concerns' and 'possible unintended consequences,' while an HHS spokesperson told NPR it is reassessing how to balance public health with 'consumer access and choice.' Dermatology experts, including American Academy of Dermatology president Dr. Susan Taylor and UCSF researcher Hunter Shain, say the move ignores extensive evidence that indoor tanning sharply raises skin‑cancer risk, noting that starting before age 20 boosts melanoma risk by nearly 50% and that the WHO classifies UV tanning devices in the same top‑tier carcinogen category as tobacco and asbestos. The decision follows Kennedy’s earlier social‑media pledge to end what he called federal 'suppression' of 'sunshine,' and comes after more than 9,000 public comments — many from tanning‑industry workers — argued the rules would infringe on personal choice and drive tanning underground. Public‑health advocates warn that rolling back the proposed rule could mean more preventable skin cancers and higher long‑term treatment costs, while industry groups continue to dispute the strength of the scientific evidence on early‑life UV exposure.

FDA and Public Health Regulation Cancer and Indoor Tanning Policy